{
    "id": 26620,
    "fullName": "MERTK over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MERTK over exp indicates an over expression of the Mertk protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10461,
        "geneSymbol": "MERTK",
        "terms": [
            "MERTK",
            "c-Eyk",
            "c-mer",
            "MER",
            "RP38",
            "Tyro12"
        ]
    },
    "variant": "over exp",
    "createDate": "05/24/2017",
    "updateDate": "07/30/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14928,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXDX-106 inhibited proliferation of patient derived gastric cancer cells overexpressing Mertk (PMID: 29285287).",
            "molecularProfile": {
                "id": 27879,
                "profileName": "MERTK over exp"
            },
            "therapy": {
                "id": 5710,
                "therapyName": "RXDX-106",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11795,
                    "pubMedId": 29285287,
                    "title": "MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29285287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10997,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXDX-106 inhibited Tam-family kinases activity in transformed cells overexpressing Mertk in culture and resulted in tumor growth inhibition in cell line xenograft models (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31).",
            "molecularProfile": {
                "id": 27879,
                "profileName": "MERTK over exp"
            },
            "therapy": {
                "id": 5710,
                "therapyName": "RXDX-106",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8954,
                    "pubMedId": null,
                    "title": "Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor",
                    "url": "http://www.sciencedirect.com/science/article/pii/S0959804916326739?via%3Dihub"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14929,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines with Braf V600E and overexpression of Mertk were resistant to Zelboraf (vemurafenib) (PMID: 29050198).",
            "molecularProfile": {
                "id": 30390,
                "profileName": "BRAF V600E MERTK over exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11796,
                    "pubMedId": 29050198,
                    "title": "mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29050198"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27879,
            "profileName": "MERTK over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30390,
            "profileName": "BRAF V600E MERTK over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}